Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Vera Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Vera Therapeutics, Inc.’s stock price such as:

• Vera Therapeutics, Inc.’s current stock price and volume
• Why Vera Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for VERA from analysts
• VERA’s stock price momentum as measured by its relative strength

About Vera Therapeutics, Inc. (VERA)

Before we jump into Vera Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Want to learn more about Vera Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Vera Therapeutics, Inc..

Vera Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Vera Therapeutics, Inc.’s stock price was $32.100.

Vera Therapeutics, Inc. is down 2.87% from its previous closing price of $33.050.

During the last market session, Vera Therapeutics, Inc.’s stock traded between $31.540 and $32.810. Currently, there are approximately 71.48 million shares outstanding for Vera Therapeutics, Inc..

Vera Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Vera Therapeutics, Inc. Stock Price History

Vera Therapeutics, Inc.’s (VERA) price is currently down 25.19% so far this month.

During the month of July, Vera Therapeutics, Inc.’s stock price has reached a high of $44.600 and a low of $31.540.

Over the last year, Vera Therapeutics, Inc. has hit prices as high as $56.050 and as low as $19.066. Year to date, Vera Therapeutics, Inc.’s stock is down 36.61%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Vera Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Vera Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Vera Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Vera Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Vera Therapeutics, Inc. (VERA) by visiting AAII Stock Evaluator.

Relative Price Strength of Vera Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Vera Therapeutics, Inc. has a weighted four-quarter relative price strength of 6.07%, which translates to a Momentum Score of 73 and is considered to be Strong.

Want to learn more about how Vera Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Vera Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Vera Therapeutics, Inc.’s stock price is $32.100, which is down 2.87% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Vera Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.